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Studies in vitro and in animal models of colorectal and hepatocellular cancers suggest that curcumin is an effective chemopreventive
agent. In this pilot trial, we investigated whether oral administration of curcumin results in concentrations of the agent in normal and
malignant human liver tissue, which are sufficient to elicit pharmacological activity. In total, 12 patients with hepatic metastases from
colorectal cancer received 450–3600mg of curcumin daily, for 1 week prior to surgery. Levels of curcumin and its metabolites were
measured by HPLC in portal and peripheral blood, bile and liver tissue. Curcumin was poorly available, following oral administration,
with low nanomolar levels of the parent compound and its glucuronide and sulphate conjugates found in the peripheral or portal
circulation. While curcumin was not found in liver tissue, trace levels of products of its metabolic reduction were detected. In patients
who had received curcumin, levels of malondialdehyde-DNA (M1G) adduct, which reflect oxidative DNA changes, were not
decreased in post-treatment normal and malignant liver tissue when compared to pretreatment samples. The results suggest that
doses of curcumin required to furnish hepatic levels sufficient to exert pharmacological activity are probably not feasible in humans.
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Curcumin [1,7-bis(4-hydroxy-3-methoxyphenyl)-1,6-heptadien-
3,5-dione] is a potent antioxidant derived from the spice turmeric.
It exerts cancer chemopreventive efficacy in a wide variety of
rodent models of carcinogenesis (Kelloff et al, 1994). In common
with several other diet-derived polyphenols, curcumin has low
systemic bioavailability (Ireson et al, 2001). This pharmacokinetic
feature of curcumin, which has been observed across several
species, is the result of poor absorption and avid metabolic
conjugation and reduction (Ireson et al, 2002; Sharma et al,
submitted for publication). Despite the evidence that curcumin is
poorly available following oral administration, there are reports
that curcumin at 50–200mgkg
 1 doses exerts biological activity
on sites distant from the locus of absorption in rodents, such as
breast (Inano and Onoda, 2002), prostate (Frank et al, 2003), lung
(Menon et al, 1995) and especially the liver (Busquets et al, 2001;
Park et al, 2001; Nanji et al, 2003). Studies on gall bladder
contractility following oral curcumin in humans suggest that
curcumin may exert biological actions at doses of 20mg (Rasyid &
Lelo 1999; Rasyid et al, 2002).
Curcumin is thought to exert its chemopreventive efficacy via
mechanisms including antioxidation and prevention of oxidative
DNA damage. In Apc
Minþ mice, a model of familial adenomatous
polyposis, dietary curcumin reduced adenoma burden (Perkins
et al, 2002b), which was accompanied by a reduction in adenoma
levels of the oxidative DNA adduct (2-deoxy-b-dierythropentafur-
anosyl)pyrimido[1,2-a]-purin-10(3H)-one (malondialdehyde-DNA
adduct, M1G) (Perkins et al, 2002a). Other mechanisms by which
curcumin may exert chemopreventive action are interference with
the transcription of the enzyme cyclooxygenase-2 (COX-2)
(Plummer et al, 1999), induction of apoptosis (Kuo et al, 1996;
Kawamori et al, 1999) and antiangiogenesis (Arbiser et al, 1998).
The concentrations of curcumin needed to exert these effects in
cells in vitro, range from 5 to 50mM (Sharma, 1976; Kunchandy and
Rao, 1990; Huang et al, 1991; Tonessan and Greenhill, 1992; Reddy
and Lokesh, 1992; Subramanian et al, 1994; Plummer et al, 1999).
Little is known about the potential pharmacological efficacy of
products of the metabolic conjugation and reduction of curcumin.
Curcumin metabolites were much less capable of suppressing
COX-2 transcription in cells in vitro than the parent compound
(Ireson et al, 2002), indicating that chemopreventive efficacy may
be in the main mediated by curcumin per se and that metabolic
conjugation and reduction constitute pharmacological deactiva-
tion steps.
The disposition of curcumin in liver tissue, portal circulation
and bile is unknown in humans. Therefore, we aimed to determine
the levels of curcumin achievable in human liver following oral
administration of curcumin. In particular, the hypothesis was
tested that oral consumption of curcumin could produce liver
tissue concentrations in humans consistent with levels shown to
exert pharmacological action in vitro. These data could help to
assess the feasibility of using curcumin as part of a strategy to
prevent the development of hepatic metastases following resection
of primary colorectal adenocarcinomas.
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Patients
A total of 12 patients (four female, eight male, aged 44–76 years)
with hepatic metastatic disease from primary colorectal adeno-
carcinomas, were recruited into the trial following approval by the
local ethics committee. All patients gave written informed consent
for their tissue to be used in the trial. Their haematological
profiles, urea and electrolytes and hepatic function were all within
normal range, as defined by the clinical laboratories of the
University Hospitals of Leicester. Four of the patients had received
preoperative chemotherapy, consisting of a 3-month course of 5-
fluorouracil and folinic acid. Their drug history included
antihypertensives (five patients), diuretics (two patients) and
simple analgesics (five). Pretreatment tissue samples of normal
and malignant liver tissue were obtained at staging laparoscopy,
which was performed to exclude peritoneal disease undetectable by
computed tomography, prior to the patient’s resection surgery.
The curcumin content in the capsules was ascertained by HPLC.
Patients (four per dose level) received a purified turmeric extract
formulated in capsules obtained from Sabinsa Corp (‘Curcumin C3
complex’, Piscataway, NJ, USA). Each capsule contained 450mg
curcumin, 30mg of desmethoxycurcumin and 20mg of bides-
methoxycurcumin. Dose levels were 1, 4 or 8 capsules daily,
translating to 450, 1800 or 3600mg of curcumin, for 1 week prior
to surgery. Samples of peripheral blood were taken 1h immedi-
ately after curcumin dosing, and hepatic resection was performed
6–7h after the last dose of curcumin. Samples of portal blood, bile
and further samples of peripheral blood were taken intraopera-
tively. Blood and tissue samples were stored for up to 10 weeks at
 801C prior to analysis.
HPLC analysis and mass spectrometry
Authentic curcumin glucuronide and curcumin sulphate were
generated by incubation with rat liver microsomes and cytosol
respectively, with appropriate cofactors (Ireson et al, 2001).
Authentic hexahydrocurcumin and hexahydrocurcuminol, pro-
ducts of the metabolic reduction of curcumin, were generated as a
mixture by reacting curcumin with sodium borohydride (Ireson
et al, 2001). The identity of the products of chemical reduction of
curcumin was validated by tandem mass spectrometry, which
confirmed the presence of the respective molecule ions (hexahy-
drocurcumin m/z¼373, hexahydrocurcuminol m/z¼375). These
species were not separated further and were available for
comparison only in impure form.
Tissues were thawed, homogenised in ammonium acetate buffer
(1 M, pH 4.6, 10% wv
 1) and extracted with ethylacetate, which
had been presaturated with ice-cold propan-2-ol. The extract was
analysed for the presence of curcumin, its two metabolic
conjugates curcumin sulphate and curcumin glucuronide and its
metabolic reduction products hexahydrocurcumin and hexahy-
drocurcuminol by HPLC (UV detection) as described by Ireson
et al (2001). The validation of the analytical method for curcumin
and the curcumin conjugates has been described by Ireson et al
(2001). Curcumin and its conjugates were detected at 420nm, the
products of curcumin reduction at 280nm. Under the extraction
and assay conditions, the limit of detection for curcumin and its
conjugates was approximately 3nM. In separate experiments, the
recovery of curcumin was determined to be 80.772.3% from
plasma, 55.3710.2% from bile and 60.374.3% and 65.875.3%
from malignant and normal liver tissue, respectively (mean7s.d.,
n¼4). We have established earlier that the recovery of curcumin
glucuronide and curcumin sulphate from rat liver tissue is poor,
between 40 and 50% (Ireson, 2002). Absence of pure hexahy-
drocurcumin and hexahydrocurcuminol confounded reliable
determination of their recovery. Identification was performed by
co-chromatography using authentic metabolic standards and,
whenever possible, by mass spectrometry using a Quattro Ultima
Platinum Mass Spectrometer (Waters, Manchester, UK). For mass
spectral analysis, samples (10ml) of eluate obtained from the HPLC
column containing suspected curcumin-derived species were dried
and solubilized in acetonitrile:water (7:3) and injected into the
mass spectrometer using a back flow of 70/30 acetonitrile/water at
50mlmin
 1 (Waters Alliance 2695 HPLC pump) using desolvation
and source temperatures of 200 and 1201C, respectively. The mass
spectrometer was tuned up to each authentic agent prior to sample
analysis. Analysis involved a scan of 40–600m/z. Tandem mass
spectrometry was used to fragment molecular ions into product
ions, argon was the collision gas. The determination of molecular
species related to curcumin proved consistently difficult due to
inherent poor sensitivity, which may be, at least in part, a function
of the negative ion polarity of the analyte species. Therefore, it was
not feasible to confirm hexahydrocurcumin and hexahydrocurcu-
minol peak identity in biological matrix extracts by mass
spectrometry. On gross extrapolation, UV spectrophotometry
was at least 10-fold more sensitive than mass spectrometry as
method of HPLC detection for these species.
Stability of curcumin and its metabolites
In the light of the fact that levels of detected analyte species were
consistently low, we ascertained that curcumin, its glucuronide
and sulphate conjugates and reduction products hexahydrocurcu-
min and hexahydrocurcuminol were sufficiently stable under
storage and assay conditions to allow meaningful interpretation of
analysis results. The stability was checked under conditions of
tissue storage at  801C (spiked tissue samples) and of the HPLC
assay at room temperature. After 3 months of storage, areas of
peaks indicative of curcumin and its metabolites in extracts from
liver tissue were unchanged. When kept after dissolution in HPLC
injection solvent (acetonitrile:water 1:1) curcumin and its
metabolites were stable for at least 12h at room temperature.
Analysis of M1G adduct levels
Extraction of genomic DNA from liver tissue obtained at staging
laparoscopy and during surgery, and analysis of M1G adduct levels
by immunoslotblot was performed as described previously by
Leuratti et al (1998) using a primary anti-M1G antibody provided
by Dr Lawrence Marnett (Vanderbilt University, TN, USA).
Discrepancies in the amount of DNA in each slot were corrected
for by staining the nitrocellulose filter with propidium iodide and
performing UV light densitometry. The limit of detection for M1G
was five adducts per 10
8 nucleotides.
RESULTS
HPLC analysis of the portal serum of three patients who had
received 3600mg curcumin furnished three peaks. These peaks
were tentatively characterised as curcumin, curcumin glucuronide
and curcumin sulphate on the basis of their retention times. The
peak areas were below the limit of quantitation and near the limit
of detection (B3n M). Unambiguous identification of these three
species was achieved by collection of the eluent at the retention
times of the respective peaks, evaporation of solvent and reanalysis
of the residues by co-chromatography using authentic curcumin,
curcumin glucuronide and curcumin sulphate (Figure 1). Mass
spectrometric analysis corroborated the chromatographic evidence
of peak identity, yielding molecule ions of m/z 543, 447 and 367 for
curcumin glucuronide, curcumin sulphate and curcumin, respec-
tively. A peak coeluting with curcumin was also found in the
peripheral circulation in two patients who had received the last
dose of curcumin 3600mg 1h prior to blood collection. Analysis of
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or 450mg of curcumin did not reveal evidence for the presence of
curcumin or its conjugates.
Curcumin, curcumin sulphate and curcumin glucuronide were
not found in bile or normal and malignant liver tissue in any of the
patients who had received curcumin. Analysis of normal liver
tissue from one patient who had received 3600mg of curcumin
daily yielded two peaks with retention times of 22 and 27min,
which indicates the presence of hexahydrocurcumin and hexahy-
drocurcuminol, products of the metabolic reduction of curcumin.
The identity of these species was further defined after isolation of
material eluting with the peaks and its reanalysis by co-
chromatography with a mixture of hexahydrocurcumin and
hexahydrocurcuminol generated by chemical reduction of curcu-
min (Figure 2). The relatively poor sensitivity of mass spectro-
metry as a means of detection of hexahydrocurcumin and
hexahydrocurcuminol confounded mass spectral verification of
peak identity.
Next, we investigated whether dietary curcumin affects levels of
oxidative DNA adducts as reflected by M1G in normal and
malignant liver tissue. Levels measured in four patients who
received curcumin 3600mg were as follows (expressed as adducts
per 10
7 nucleotides): 4.370.4 in normal tissue obtained during
staging laparoscopy (pretreatment), 6.373.8 in normal surgical
tissue (post-treatment), 2.571.5 in pretreatment malignant tissue
and 6.375.2 in post-treatment malignant surgical tissue. The
difference between pre- and post-treatment values was significant
(Po0.05 by Student’s t-test). A very similar difference in M1G
levels between pre- and post-treatment samples was observed in
patients who received 450 or 1800mg curcumin. For orientation,
these values compare with a mean of 4.5 adducts per 10
7
nucleotides reported in normal rat liver (Sharma et al, 2001a)
for orientation, these values compose with a mean of 4.5 adducts
per 10
7 nucleotides reported in rat liver (Sharma et al, 2001a) and
with 5–10 adducts per 10
7 nucleotides in healthy liver tissue from
humans (Chaudhary et al, 1994). The fact that levels were
consistently increased post-treatment irrespective of curcumin
dose is counterintuitive in the light of the absence of curcumin-
derived species in the livers of patients on the low dose, and its
presence at extremely low levels in only one of the patients on
3600g curcumin (see above). Therefore, one might expect a priori
either that there is no difference in M1G levels between pre- and
post-treatment samples, or that, if curcumin was present at
sufficient amounts, M1G levels are decreased post-treatment. In the
light of all these considerations, we surmise that the observed
difference in oxidative DNA adduct levels between pre- and post-
treatment samples is unrelated to curcumin. It is conceivable that
the difference was caused using the Pringle manoeuvre during
post-treatment surgery. This procedure, which is widely used
during liver resection to reduce bleeding, involves occlusion of the
hepatic artery and portal vein. Consequently, Kupffer cells are
activated, resulting in the production of reactive oxygen species
and cytokines, thus precipitating oxidative stress (Colletti et al,
1990; Wang et al, 1994). While we did not further investigate a
possible link between Pringle manoeuvre and rise in M1G levels in
patients who did not receive curcumin, our suspicion of an
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Figure 1 HPLC analyses of an extract of (A) portal blood of a patient who received curcumin 3600mg daily for a week; (B, i) an extract of HPLC solvent
eluting with the peak with retention time 25min in (A) (broken arrow), (B, ii) a solution of authentic curcumin glucuronide and (B, iii) a mixture of i and ii;
(C, i) an extract of HPLC solvent eluting with the peak with retention time 31min in (A) (solid arrow), (C, ii) a solution of authentic curcumin sulphate, and
(C, iii) a mixture of i and ii; (D, i) an extract of HPLC solvent eluting with the peak with retention time 37min in (A) (block arrow), (D, ii) a solution of
authentic curcumin, and (D, iii) a mixture of i and ii. Detection was by UV spectrophotometry at 420nm. It is important to point out that the peaks of
curcumin and curcumin conjugates are accompanied by peaks of the respective desmethoxy analogues at lower abundance, which is a corollary of the fact
that desmethoxycurcumin and bisdesmethoxycurcumin are inevitable constituents of the curcumin formulation (at 10%, Ireson et al, 2001). The indication of
presence of peaks for desmethoxycurcumin, desmethoxycurcumin glucuronide and desmethoxycurcumin sulphate accompanying the respective peaks of
the curcumin-derived species is consistent with the inferences as to peak identity. ‘mAU’ denotes milli absorbance units. Surgery was conducted 6h after the
last of seven daily doses of curcumin. The chromatograms that are from one patient are representative of three of the four patients who received curcumin
at 3600mg. For details of surgery, sample preparation and HPLC analysis, see Materials and methods.
Curcumin and its metabolites in hepatic tissue and portal blood
G Garcea et al
1013
British Journal of Cancer (2004) 90(5), 1011–1015 & 2004 Cancer Research UK
C
l
i
n
i
c
a
lassociation was supported by a gross correlation between these
levels and the duration of application of the Pringle clamp.
DISCUSSION
The results presented above provide the first evidence in humans
that oral administration of curcumin furnishes trace levels of the
parent compound and its metabolites in the liver and portal
circulation. However, the levels of curcumin recovered were below
10
 8 M, thus of an order of magnitude that is unlikely to exert
pharmacological effects in the light of results obtained in
experiments in which cells in vitro were exposed to curcumin
(see e.g., Sharma, 1976; Kunchandy and Rao, 1990; Huang et al,
1991; Reddy and Lokesh, 1992; Tonessan and Greenhill, 1992;
Subramanian et al, 1994; Plummer et al, 1999).
The lack of quantifiable levels of curcumin in plasma is
consistent with recent clinical reports in which doses of up to
180mg of curcumin failed to establish detectable plasma levels
(Sharma et al, 2001b) and very high doses (up to 8g) yielded
curcumin peak levels of only approximately 0.5–2mM within 1h of
oral administration (Cheng et al, 2001). Traces of conjugated
curcumin metabolites were detected in the urine of humans who
had received doses of 1800–3600mg daily (Sharma et al,
submitted for publication). The presence of curcumin conjugates
in the portal circulation is consistent with reports that curcumin
undergoes glucuronidation and sulphation in the intestine of both
humans and rodents (Ireson et al, 2001). We have recently shown
that oral consumption of up to 3600mg curcumin leads to
curcumin concentrations of 10nmolg
 1 tissue in human colorectal
mucosa, levels that might be high enough to exert biological
efficacy (Garcea et al, submitted). However, only trace levels of the
parent compound were found in the peripheral circulation.
Considerable interest exists in the use of curcumin as a
chemopreventive agent (Kelloff et al, 1994). The results of the
analytical determination presented here render it unlikely that
curcumin holds any potential in the chemoprevention of hepatic
malignancies. Consistent with this notion, curcumin did not
reduce levels of M1G adducts in normal or malignant hepatic tissue
at any of the doses used in this study. Nevertheless, this latter
conclusion has to be drawn with utmost caution in the light of the
unexpected increase in M1G adduct levels post-treatment, which
was probably unrelated to treatment with curcumin and might
have been rather a function of the surgical procedure used in the
generation of post-treatment tissue. For comparison, dietary
curcumin (2%) reduced M1G levels in colon mucosa of rats that
had been challenged with carbon tetrachloride, an oxygen radical-
generating hepatotoxicant, but failed to affect M1G levels in rat
liver tissue (Sharma et al, 2001a). Furthermore, at 0.2% in the diet
curcumin decreased M1G levels in intestinal adenomas of Apc
Minþ
mice (Perkins et al, 2002a).
The poor availability of curcumin in humans shown here
impacts also on the feasibility of its role as a modulator of
chemotherapy-induced apoptosis in tissues remote from the
gastrointestinal tract, as discussed recently (Somasundaram et al,
2002; Mitchell, 2003). In conclusion, clinical trials of curcumin
should focus on the prevention of colorectal tumours but not
tumours distant from the locus of absorption such as the liver.
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